Transcription of TS-1+CDDP(SP) 療法とカペシタビン+CDDP(XP) 療法の 無作 …
1 HERBIS-4A HER2 TS-1+ cddp (SP) + cddp (XP) II 0. HER2 TS-1+ cddp (SP) + cddp (XP) II II HER2 TS-1+ cddp (SP) + cddp (XP) (Response rate RR) (Progression-free survival PFS) (Overall survival OS) (Time to treatment failure TTF) 1 Stage N0 N1 N2 N3 T/N M1 T1a (M), T1b (SM) IA IB IIA IIB IV T2 (MP) IB IIA IIB IIIA T3 (SS) IIA IIB IIIA IIIB 1) HER2 R0 2) 3) 20 75 4) PS(ECOG) 0 2 5) 6) 14 ( 2 )
2 3,000/mm3 1,500/mm3 100,000/mm3 14 AST GOT 100IU/L ( 150IU/L) ALT GPT 100IU/L ( 150IU/L) 60mL/min* *24 Cockcroft-Gault (140 ) / 72 ( ) 7) 3 8) 9) 1) 2) 5 3) 4) 5) T4a (SE) IIB IIIA IIIB IIIC T4b (SI) IIIB IIIB IIIC IIIC T/N M1 6 6) HBs 7) 1 4 8) 9) 10) 11) 12) ( TS-1) 20/25 T20/T25 300 ( cddp ) 50mg/100mg II A TS-1+ cddp SP TS-1 80mg/m2 day1 day22 1 2 14 cddp day8 60mg/m2 2 5 1 B + cddp XP 2000mg/m2 day1 day15 1 2 7 cddp day1 80mg/m2 2 3 1 Performance Status(ECOG).
3 0,1/ 2 (A ) TS-1+ cddp SP 3W 2W 5 1 (B ) + cddp XP 2W 1W 3 1 HER2 PS 0-2 20 75 100 50 3 2011 11 1 2014 10 31 2 2011 11 1 2013 10 31 1 2014 10 31 (1) 550-0002 1-18-35 IP 505 9:30 17:00 ( ) TEL 06-6447-7106, FAX 06-6447-7108 (2) OGSG 540-0003 1-14-2 2F TEL 06-6790-7121, FAX 06-4790-7122
